Chelsea and Westminster Hospital
London, United Kingdom
Location status: Recruiting
NCT Number: NCT05177510
The number of women having an induction of labour is increasing and is currently used in 33% of pregnancies for a range of medical reasons. The majority of women are admitted to hospital to have their labour induced, using methods which are protracted and associated with a poor birth experience, making them both costly and unpopular. Further, current methods of outpatient induction are unsuitable, unsafe and/or have a poor acceptability. The COVID-19 pandemic has driven a reduction in the number of face-to-face interactions taking place across all areas of medicine. Proving the efficacy and safety of Mifepristone would significantly reduce pre-labour admission rates and hospital length of stay for pregnant women, who are at particularly higher risk of COVID-19, and reduce delivery costs.
Interested in participating?
Request Info18 year and older
Female
Interventional
Phase 2
London, United Kingdom
Location status: Recruiting
The study is a double blinded, two arms, multi-centre randomised controlled clinical trial to investigate the clinical effectiveness, safety and resource utilisation of intervention for the induction of labour in women admitted to the hospital. Subjects will be randomised 1:1 to one of the two arms to receive:
Arm 1: Mifepristone + standard of care Arm 2: Placebo + standard of care
The study treatment will commence from the administration of the Mifepristone or placebo. The participants will be assessed 2 days after treatment regimen will be completed as an in-patient.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
i. sexually transmitted infections (active infections only) ii. bleeding disorders, on anticoagulants, steroid or aspirin therapy iii. prior uterine operations (Caesarean Section or myomectomy)
Progestin Antagonist
Placebo
Time frame: up to 2 days after administration of intervention
To determine proportion of women who do not require an induction of labour within 2 days of intervention with mifepristone (superiority).
Time frame: up to 6 weeks after delivery
Occurrence of changes in clinical outcomes such as cervical ripening and interval to delivery.
Time frame: after delivery and up to 6 weeks after delivery
Patient reported outcomes will be collected following administration of questionnaires after delivery and up to 6 weeks after delivery
Time frame: up to 6 weeks after delivery
Incidence and severity of adverse events in maternal and neonatal
Contact information is provided by the study sponsor or research team.
Arnold Xhikola
CONTACT
Tess Cheetham
CONTACT
Chelsea and Westminster NHS Foundation Trust
Other
Acronym: MOLI
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06591247
Balloon Induction, Cervical Ripening
Kfar Saba, Central District, Israel
View Trial DetailsNCT07366359
Cervical Ripening, Female Urogenital Diseases and Pregnancy Complications
Hanoi, Vietnam
View Trial DetailsNCT07237880
Labor, Induced
Hadera, Israel
View Trial DetailsNCT07272785
Childbirth Experience, Humans
Turku, Finland
View Trial Details